Bayer taps Roche's Foundation Medicine for Vitrakvi diagnostic development
fiercebiotech | May 29, 2019
Bayer has teamed up with Foundation Medicine to develop genetic diagnostic tests for several of its cancer therapies-starting with the tissue-agnostic Vitrakvi in solid tumors with TRK fusion mutations.Acquired from Loxo Oncology, Bayer’s Vitrakvi (larotrectinib) was the first targeted cancer drug to be developed and approved specifically for a pan-cancer indication, based not on a tumor’s organ site but on its genetic makeup.